Unicycive Therapeutics, Inc. announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (UK) has completed review of the Clinical Trial Application (CTA) and has issued a notice of acceptance for UNI-494 first-in-human Phase 1 study in healthy volunteers.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8094 USD | -10.69% | -3.15% | -6.72% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.72% | 30.3M | |
+46.19% | 55.7B | |
+40.15% | 39.91B | |
-6.14% | 39.57B | |
-6.65% | 28.16B | |
+12.33% | 26.3B | |
-21.78% | 18.94B | |
+28.38% | 12.17B | |
+24.18% | 12.12B | |
-0.35% | 12.12B |
- Stock Market
- Equities
- UNCY Stock
- News Unicycive Therapeutics, Inc.
- Unicycive Therapeutics, Inc. Announces Medicines and Healthcare Products Regulatory Agency in the United Kingdom Complete Review of the Clinical Trial Application and Issue A Notice of Acceptance for UNI-494 First-In-Human Phase 1